Washington, DC – Congressional Diabetes Caucus Co-Chairs Tom Reed (R-NY) and Diana DeGette (D-CO) today celebrated a policy change that the caucus had long advocated to modernize Medicare coverage: The federal government will now permit coverage of costs for Continuous Glucose Monitoring (CGM) by patients who track their data using smartphones, tablets and other personal electronic devices.
Washington, DC – There are multiple barriers to reducing the surging cost of insulin; Congressional Diabetes Caucus co-chairs Diana DeGette (D-CO) and Tom Reed (R-NY) have found that value-based contracting is one avenue that is worth exploring. DeGette and Reed today released the latest insights from their outreach to stakeholders as part of their ongoing investigation of insulin costs.
Washington, DC – In their continuing inquiry into skyrocketing costs for insulin, Diabetes Caucus co-chairs Rep. Diana DeGette (D-CO) and Rep. Tom Reed (R-NY) today sent five more letters to health care industry stakeholders seeking further information about health plan benefit design and drug discount programs offered by pharmaceutical companies.
Washington, DC – The co-chairs of the Congressional Diabetes Caucus, Rep. Diana DeGette (D-CO) and Rep. Tom Reed (R-NY), have released a bipartisan request for stakeholders to provide information about whether health plans can pay for insulin based on how well the particular drug product works for patients.
Washington, D.C.- Reps. Tom Reed (R-NY) and Diana DeGette (D-CO), co-chairs of the Congressional Diabetes Caucus, commend the House passage today of the National Clinical Care Commission Act.
Washington, DC – The co-chairs of the Congressional Diabetes Caucus, Reps. Diana DeGette (D-CO) and Tom Reed (R-NY), are taking next steps in their inquiry into the rising price of insulin after meetings during the past two months with stakeholders at major trade associations and in the diabetes community.